Magnetic responsive embolization agents, methods of making and testing embolization agents

Abstract

The disclosure provides a magnetically responsive embolus, a preparation method and a test method of the embolus. The magnetically responsive embolus comprises: a first alloy and a second alloy prepared by mixing alloying, the first alloy is a eutectic alloy composed of metal indium and metal tin, and the second alloy is a eutectic alloy composed of metal gallium, metal indium and metal tin; and ferromagnetic particles uniformly dispersed in the interior of the alloyed first alloy and second alloy. The embolus has a significant undercooling effect and can remain in a liquid state below the melting point of the alloy after mixing alloying. Through the ferromagnetic particles in the interior, the embolus can respond to an external preset magnetic field, drive the entire embolus to anchor according to the magnetic field, and trigger the embolus to solidify under high-frequency disturbance of the magnetic field, so as to realize controllable solidification embolization after precise positioning.

Description

Technical Field

[0001] The embodiments of this application relate to the technical field of medical devices, and more particularly to a magnetically responsive embolic agent, a method for preparing the embolic agent, and a method for testing the embolic agent. Background Technology

[0002] Current embolization materials for blood vessels typically include metal coils, gelatin microspheres, and liquid embolizing gels. However, these materials face multiple technical bottlenecks in interventional applications, making it difficult to meet actual embolization needs.

[0003] First, the aforementioned embolization materials lack active navigation capabilities and can only be passively delivered by blood flow or mechanically pushed by catheters. They cannot accurately navigate and locate in complex, narrow, and high-velocity vascular networks, and are particularly difficult to deliver against the flow of blood. This can easily lead to problems such as embolization material drift and misalignment of the embolization location. Furthermore, they are easily lost in the blood flow and cannot form a stable embolism.

[0004] Secondly, there is insufficient embolization stability. For example, the material is easily dispersed and migrated under the impact of high-speed blood flow, resulting in incomplete embolization and a high rate of vascular recanalization.

[0005] In addition, some of the aforementioned embolic materials lack imaging properties, making it difficult to track the movement of the embolic materials in real time.

[0006] Meanwhile, among the aforementioned embolization materials, liquid embolization adhesive is usually brittle after curing, easily breaks, and has poor controllability; metal spring coil embolization has limited density and is prone to recurrence.

[0007] Furthermore, the aforementioned embolization materials lack controllable phase change characteristics, meaning they cannot flexibly regulate flow and solidification states in motion environments, making it difficult to adapt to embolization requirements in different environments. Summary of the Invention

[0008] In view of this, embodiments of the present disclosure provide an embolic agent, a method for preparing the embolic agent, and a method for testing the embolic agent.

[0009] In a first aspect, embodiments of this disclosure provide a magnetically responsive embolic agent, the magnetically responsive embolic agent comprising: The first alloy and the second alloy are prepared by mixed alloying. The first alloy is a eutectic alloy composed of metallic indium and metallic tin, and the second alloy is a eutectic alloy composed of metallic gallium, metallic indium and metallic tin. Ferromagnetic particles are uniformly dispersed within the alloyed first and second alloys.

[0010] In some alternative embodiments, the melting points of the first and second alloys are greater than or equal to 42 degrees Celsius and less than or equal to 45 degrees Celsius.

[0011] In some alternative embodiments, the alloyed first and second alloys have a supercooling of 10 degrees Celsius to exhibit a fluid, cold metastable state in an environment within 10 degrees Celsius below their melting points.

[0012] In some alternative implementations, the size of the ferromagnetic particles is on the micrometer scale; Ferromagnetic particles are used to respond to a pre-set magnetic field outside the embolic agent and disrupt the cold metastable state in order to solidify the first and second alloys, which are below the melting point and have fluidity.

[0013] In some alternative implementations, ferromagnetic particles are used to control the movement of the first and second alloys alloyed based on a pre-set magnetic field outside the embolic agent.

[0014] Secondly, embodiments of this disclosure provide a method for preparing an embolic agent, the method comprising: The first alloy and the second alloy are mixed in a preset mass ratio and alloyed at a preset temperature to obtain a mixed alloy matrix. The mixed alloy matrix and ferromagnetic particles are placed in a hydrochloric acid solution and stirred at 60 degrees Celsius to uniformly disperse the ferromagnetic particles in the mixed alloy matrix and remove the oxide layer on the surface of the mixed alloy matrix, thereby obtaining a magnetically responsive embolic agent.

[0015] Thirdly, embodiments of this disclosure provide a method for testing an embolic agent, the method comprising: The embolic agent is melted into a liquid state at an temperature greater than 45 degrees Celsius. Liquid embolic agents are introduced into a pre-set vascular model, which provides an ambient temperature of 37 degrees Celsius. The embolic agents exhibit a fluid, cold metastable state within the vascular model. The movement of a cold metastable embolic agent within a vascular model is controlled using a pre-set magnetic field. In response to the cold metastable state of the embolic agent, it moves to the target location within the vascular model. The high-frequency perturbation of the magnetic field disrupts the cold metastable state of the embolic agent, thereby accelerating the coagulation of the embolic agent.

[0016] In some alternative implementations, the vascular model includes multiple simulated blood vessels of different diameters, with the connection points of the multiple simulated blood vessels forming different turning angles.

[0017] Accordingly, the movement of a cold metastable embolic agent within a vascular model is controlled using a pre-set magnetic field, including: The embolic agent is controlled to move in simulated blood vessels of different diameters and at joints with different turning angles using a preset magnetic field.

[0018] In some alternative implementations, at least one simulates a dynamic water flow with different velocities within a blood vessel.

[0019] Accordingly, the movement of a cold metastable embolic agent within a vascular model is controlled using a pre-set magnetic field, including: The embolic agent is controlled to move downstream and upstream at different flow rates using a preset magnetic field.

[0020] In some alternative implementations, after controlling the movement of a cold metastable embolic agent within a vascular model using a preset magnetic field, the method further includes: The mobility of embolic agents can be detected using X-rays; Accordingly, after disrupting the cold metastable state of the embolic agent using high-frequency perturbations of the magnetic field, the method further includes: X-rays are used to detect the ability of an embolic agent to block the target location after solidification.

[0021] To address the current issues of lack of active navigation and poor controllability in embolization materials, the embodiments of this disclosure provide a magnetically responsive embolizing agent, a method for preparing the embolizing agent, and a testing method. By mixing a first alloy and a second alloy, the embolizing agent can remain in a liquid state below the melting point of the first alloy, thereby achieving a supercooling effect. Through its internal ferromagnetic particles, it can respond to an externally preset high-frequency magnetic field, driving the entire embolizing agent to move according to the magnetic field guidance, thus achieving active navigation. It can also disrupt the cold metastable state under high-frequency disturbances of the magnetic field, triggering accelerated solidification of the embolizing agent, achieving precise positioning and controllable solidification for embolization. Furthermore, during the movement of the embolizing agent, X-ray imaging and tracking can be achieved. Attached Figure Description

[0022] Other features, objects, and advantages of this disclosure will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings. The drawings are for illustrative purposes only and are not intended to limit the invention. In the drawings: Figure 1A This is a schematic diagram of the liquid magnetically responsive embolic agent of this disclosure; Figure 1B This is a schematic diagram of the movement of the liquid magnetically responsive embolic agent of this disclosure; Figure 2 This is a flowchart of process 200 according to an embodiment of the method for preparing an embolic agent according to the present disclosure; Figure 3 This is a schematic diagram of the operational process for preparing an embolic agent according to this disclosure; Figure 4 A flowchart of process 400 according to an embodiment of the test method for embolic agents according to the present disclosure; Figure 5 This is a schematic diagram of the movement of the embolic agent according to this disclosure and the embolization process after breaking the cold metastable state. Detailed Implementation

[0023] The present disclosure will now be described in further detail with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and not intended to limit it. Furthermore, it should be noted that, for ease of description, only the parts relevant to the invention are shown in the accompanying drawings.

[0024] It should be noted that, unless otherwise specified, the embodiments and features described in this disclosure can be combined with each other. This disclosure will now be described in detail with reference to the accompanying drawings and embodiments.

[0025] In some alternative implementations, the magnetically responsive embolic agent can be composed of a variety of metals and can be in liquid or solid states depending on the temperature.

[0026] Specifically, since the embolic agent needs to have both a stable framework structure and the ability to remain liquid at body temperature, the embolic agent may include a mixed alloy matrix prepared by mixing the first alloy and the second alloy.

[0027] The mixed alloy matrix obtained by alloying the first alloy and the second alloy can have fluidity at high temperatures and a solid skeleton and long-term structural stability after solidification.

[0028] In some cases, the first alloy can be, for example, a binary eutectic alloy or a binary near-eutectic alloy composed of indium and tin. Eutectic alloys refer to alloy mixtures that can directly complete solid-liquid transformation at the lowest melting point temperature under certain proportions. Compared with non-eutectic alloys, eutectic components have a narrower melting point range and a clearer phase transformation process, making it easier to control the phase transformation process of the embolizing agent.

[0029] Near-eutectic alloys are alloy systems that are close to eutectic compositions. Their melting point range is similar to that of eutectic alloys, which can also meet the requirements for phase transformation process control, and the composition selection is more flexible.

[0030] Furthermore, the second alloy can be, for example, a ternary eutectic alloy or a ternary near-eutectic alloy composed of gallium, indium and tin.

[0031] Among them, eutectic indium tin alloy and eutectic gallium indium tin alloy can be mixed at a mass ratio of 4:3 to obtain gallium indium tin alloy matrix.

[0032] Specifically, during the alloying process, the eutectic indium tin alloy and the eutectic gallium indium tin alloy can be placed in a high-temperature environment of 300 degrees Celsius for 6 hours for alloying treatment, and the eutectic indium tin alloy and the eutectic gallium indium tin alloy are continuously mechanically stirred to ensure that the multiphase alloy is mixed uniformly.

[0033] In the embolic agent of this embodiment, in order to achieve the magnetic response capability of the embolic agent, a magnetic metal, such as ferromagnetic particles, can be added to the mixed alloy matrix after the first alloy and the second alloy are alloyed. Since the ferromagnetic particles themselves have ferromagnetic properties, they can respond to the preset magnetic field applied externally. They can be used to realize the active movement and navigation of the embolic agent under the drive of the external magnetic field, or they can be used to trigger the phase change solidification of the embolic agent through high-frequency disturbance of the magnetic field.

[0034] In some cases, the melting point of the mixed alloy matrix can be set at 42 degrees Celsius or greater and 45 degrees Celsius or less by using a ratio of components with different melting points of the first and second alloys. Accordingly, under normal conditions, the embolic agent with the mixed alloy matrix can be solid at temperatures below 42 degrees Celsius, i.e., solid at most body temperatures.

[0035] Furthermore, the hybrid alloy matrix also has a supercooling of 10 degrees Celsius, meaning that the hybrid alloy matrix can cause the embolic agent to exhibit a supercooling effect within a range of 10 degrees Celsius below the aforementioned melting point.

[0036] The supercooling effect refers to the phenomenon that a liquid alloy can remain in a fluid liquid state without solidifying when the temperature drops below its melting point. This state of liquid is called the cold metastable state.

[0037] Based on this, the embolic agent can stably maintain a fluid cold metastable state in normal human body temperature environment, that is, within 10 degrees Celsius below the melting point of the mixed alloy matrix, to meet the fluidity requirements during delivery in interventional embolization.

[0038] Specifically, refer to Figure 1A , Figure 1A The present disclosure illustrates liquid magnetically responsive embolic agents, such as... Figure 1A As shown, the embolic agent with this hybrid alloy matrix can maintain a fluid, cold metastable state in the normal human body temperature environment, and can remain liquid during delivery. This facilitates the passage of narrow and complex vascular branches under the drive of an external magnetic field, adapting to the embolization requirements of different vascular structures. It satisfies the requirement for fluidity of the embolic agent during delivery, and does not spontaneously coagulate during delivery.

[0039] Furthermore, based on the fact that ferromagnetic particles added inside the hybrid alloy matrix can respond to an external magnetic field, thereby controlling the overall movement of the embolic agent and achieving active navigation, [reference needed]. Figure 1B , Figure 1B This invention illustrates the movement of a liquid magnetically responsive embolic agent, which can move under the influence of an external magnetic field according to... Figure 1B Move as shown.

[0040] Furthermore, the ferromagnetic particles in the embolic agent can mechanically stimulate the embolic agent through high-frequency disturbances of an external magnetic field after the embolic agent reaches the target location in the blood vessel. This disrupts the cold metastable state of the hybrid alloy matrix and triggers a phase transition in the embolic agent. Without changing the environmental conditions, the hybrid alloy matrix can be rapidly solidified at the target location to complete the embolization operation. This achieves flexible and controllable regulation of the flow and solidification state of the embolic agent, adapting to the embolization needs of different vascular environments.

[0041] In addition, the ferromagnetic particles in the embolic agent have high X-ray radioblocking properties, and can be visualized in real time by X-rays during the intervention without the need for additional contrast agents. This allows operators to track the position and movement of the embolic agent in real time, improving the accuracy of the interventional procedure.

[0042] Based on this, the alloyed first and second alloys allow the embolic agent to remain liquid in an environment below the melting point of the first alloy, thereby achieving a supercooling effect. Through the ferromagnetic particles enriched on its surface, it can respond to an external preset magnetic field, driving the entire embolic agent to move according to the magnetic field guidance to achieve active navigation. It can also generate mechanical stimulation under high-frequency disturbances of the magnetic field, disrupting the cold metastable state and triggering the solidification of the embolic agent, achieving precise positioning and controllable solidification embolization. Furthermore, during the operation of the embolic agent movement, X-ray imaging and tracking of the embolic agent can be achieved.

[0043] In some alternative implementations, refer to Figure 2 The diagram illustrates a process 200 of an embodiment of a method for preparing an embolic agent according to the present disclosure, the method comprising the steps 201 to 203: Step 201: Mix the first alloy and the second alloy according to a preset mass ratio, and perform alloying treatment on the mixture at a preset temperature to obtain a mixed alloy matrix.

[0044] The first alloy is a eutectic alloy composed of indium and tin, and the second alloy is a eutectic alloy composed of gallium, indium and tin.

[0045] In this step, the first and second alloys can be mixed in a container to obtain a mixed alloy matrix.

[0046] Specifically, the first alloy and the second alloy can be mixed in a mass ratio of 4:3.

[0047] Furthermore, the mixed first alloy and second alloy are heated at a high temperature of 300 degrees Celsius until the two metals are completely melted into a liquid state. The first alloy and second alloy are then mechanically stirred to mix them evenly. After cooling, a mixed alloy matrix can be obtained.

[0048] Step 202: The mixed alloy matrix and ferromagnetic particles are placed in a hydrochloric acid solution and stirred to uniformly disperse the ferromagnetic particles in the mixed alloy matrix and remove the oxide layer on the surface of the mixed alloy matrix, thereby obtaining a magnetically responsive embolic agent.

[0049] In this step, the size of the ferromagnetic particles can be, for example, on the micrometer scale.

[0050] Further, refer to Figure 3 , Figure 3 A schematic diagram of the publicly disclosed operational process for preparing embolic agents is shown, such as... Figure 3 As shown, after obtaining a homogeneous mixed alloy matrix, ferromagnetic particles can be slowly added to the mixed alloy matrix while it is being stirred.

[0051] Further, the mixed alloy matrix with added ferromagnetic particles is placed in a hydrochloric acid solution and stirred.

[0052] In this step, based on the added ferromagnetic particles, mechanical stirring can ensure that the ferromagnetic particles are uniformly dispersed and anchored inside the mixed alloy matrix.

[0053] Furthermore, in the presence of hydrochloric acid solution, the oxide layer on the surface of the mixed alloy matrix can be removed to obtain a magnetically responsive embolic agent.

[0054] In this process, removing the oxide layer on the surface can reduce the surface tension of the hybrid alloy matrix, which is beneficial for the movement of the embolic agent in the blood vessel, improves the response efficiency under subsequent high-frequency magnetic field disturbances, and does not excessively damage the overall structure of the hybrid alloy matrix.

[0055] like Figure 3 As shown, based on the added ferromagnetic particles, when a high-frequency magnetic field is applied to the mixed alloy matrix containing ferromagnetic particles inside the container from outside the container, the ferromagnetic particles can form mechanical stimulation under the interference of the high-frequency magnetic field, which can disrupt their cold metastable state and promote liquid-solid phase transformation.

[0056] Based on this, by alloying the first alloy and the second alloy, a mixed alloy matrix with supercooling capability is obtained. Then, by adding ferromagnetic particles, magnetic response capability is achieved without destroying the supercooling characteristics of the alloy itself.

[0057] In some alternative implementations, refer to Figure 4 This illustrates a process 400 of an embodiment of the testing method for the embolic agent of this disclosure. The process 400 includes the following steps 401 to 404: Step 401: Melt the embolic agent into a liquid state at an environment greater than 45 degrees Celsius.

[0058] In this step, during the testing of the magnetically responsive embolic agent prepared above, the embolic agent can first be melted into a liquid state.

[0059] Specifically, since the melting point of the embolic agent is greater than or equal to 42 degrees Celsius and less than or equal to 45 degrees Celsius, simply raising the ambient temperature to above 45 degrees Celsius will allow the entire embolic agent to completely melt into a fluid liquid, thus preparing it for subsequent testing.

[0060] In some cases, in order to better melt all the solid crystal nuclei inside the embolic agent and achieve a supercooling of 10 degrees Celsius, a higher temperature can be used to melt the embolic agent, such as 70 degrees Celsius.

[0061] Therefore, it is ensured that the molten embolic agent can maintain its liquid fluidity in an environment within 10 degrees Celsius below its melting point.

[0062] Step 402: The liquid embolizing agent is introduced into the preset vascular model.

[0063] The vascular model includes several different simulated blood vessels.

[0064] Based on the embolic agent melted in step 401, in this step, based on the aforementioned vascular model, the liquid embolic agent can be introduced into the inlet of the vascular model.

[0065] The temperature of the vascular model is 37 degrees Celsius, so that the embolic agent can be introduced into the vascular model to provide an operating environment of 37 degrees Celsius.

[0066] Based on this, since the ambient temperature of 37 degrees Celsius provided by the vascular model is lower than the melting point temperature of the embolic agent and is within the range of supercooling, the embolic agent can stably maintain a fluid, cold metastable state and will not coagulate prematurely to block the inlet, thus providing favorable conditions for subsequent control of the movement of the embolic agent.

[0067] Step 403: Use a preset magnetic field to control the movement of the cold metastable embolic agent within the vascular model.

[0068] In this model, each simulated blood vessel can have a different diameter to test the ability of the embolic agent to move in blood vessels of different diameters.

[0069] Specifically, the vascular model can be, for example, a silicone stenosis model, a wide artery model, and / or an aneurysm model that replicates the structure of real human blood vessels.

[0070] Furthermore, multiple simulated blood vessels were connected at different turning angles, such as 30 degrees, 60 degrees, and 90 degrees, to test the mobility of the embolic agent at different turning angles.

[0071] Furthermore, dynamic water flow with different velocities is used in one or more simulated blood vessels, for example, velocities of 5 mL / s to 10 mL / s, to simulate the movement of the embolic agent in blood vessels with different blood flow velocities.

[0072] Based on the embolic agent imported into the vascular model in step 402 above, in this step, a preset external magnetic field can be placed on the outside of the vascular model, and by adjusting the position and intensity of the external magnetic field, the liquid embolic agent in a cold metastable state can be guided to move along the simulated blood vessel to the target position.

[0073] During the movement of the liquid embolic agent, its real-time position can be observed by transillumination with X-rays, thereby testing the autoradiographic effect of the embolic agent.

[0074] Furthermore, based on simulated blood vessels of different diameters, an external magnetic field can be used to control the movement of the embolic agent in simulated blood vessels of different diameters by controlling the iron element on the surface of the embolic agent, thereby testing the ability of the embolization agent to pass through blood vessels of different diameters.

[0075] Furthermore, based on the connection points with different turning angles between simulated blood vessels, an external magnetic field can be used to control the movement of the embolic agent at connection points with different turning angles by controlling the iron element on the surface of the embolic agent, thereby testing the ability of the embolic agent to travel between blood vessels connected at different angles.

[0076] Furthermore, based on the dynamic water flow in the simulated blood vessel, an external magnetic field can be used to control the iron element on the surface of the embolic agent to control its downstream and upstream movement in the simulated blood vessel at different water flow rates, thereby testing the ability of the embolic agent to flow downstream and upstream in blood vessels at different blood flow rates.

[0077] Based on this, by using vascular models with different parameters, the active navigation capability and magnetically controlled movement performance of the embolic agent in various simulated vascular environments can be comprehensively tested, and the actual effect of magnetic response driving the embolic agent to actively travel can be directly verified. At the same time, based on the ferromagnetic particles enriched on the surface of the embolic agent or its own second alloy composed of gallium, tin and indium, the X-ray imaging effect of the embolic agent can be clearly observed without additional contrast agent, verifying the reliability of the embolic agent's imaging performance.

[0078] Step 404: In response to the cold metastable embolic agent moving to the target location within the vascular model, the cold metastable state of the embolic agent is disrupted by high-frequency perturbation of the magnetic field to coagulate the embolic agent.

[0079] The target location is located within the vascular model and is used to characterize the location in the blood vessel where embolization is required.

[0080] Based on the navigation control of the liquid embolizing agent in the vascular model in step 403 above, and based on the pre-set target position, the embolizing agent can be moved to the target position by controlling the iron element on the surface of the embolizing agent using an external magnetic field.

[0081] Furthermore, after the liquid embolic agent moves to the target location, the magnetic field can be adjusted to a high-frequency perturbation magnetic field so that the first and second alloys enriched in the embolic agent are mechanically stimulated under the action of the high-frequency magnetic field.

[0082] Furthermore, based on mechanical stimulation, the first and second alloys can disrupt the cold metastable equilibrium, triggering a phase transition in the liquid embolizing agent, which then rapidly solidifies at the target location, completing the embolization process.

[0083] Specifically, refer to Figure 5 , Figure 5 The solidification process of the embolic agent of this disclosure after being disturbed by a magnetic field and breaking its cold metastable state is shown.

[0084] like Figure 5 As shown in the figure, the left image shows the initial liquid metal. A high-frequency magnetic field is applied to the embolic agent through an external magnetic field, which accelerates the solidification of the embolic agent and thus achieves the effect of embolization at the target location.

[0085] Furthermore, the right figure shows the embolic agent after phase change coagulation. After the embolic agent coagulates, the occlusion effect of the coagulated embolic agent on the target location in the blood vessel model can be observed by X-ray to verify the actual performance of the embolic agent disclosed in this invention in controllable coagulation embolization at the target location, confirm the tightness and stability of the occlusion after the embolization operation, and further verify the actual use effect of the magnetically responsive embolic agent.

[0086] In some cases, the flow velocity of water in simulated blood vessels near the target location can also be observed to determine whether the embolization of the embolic agent at the target location has an adverse effect on the water flow in other nearby simulated blood vessels.

[0087] Based on this, by simulating various environmental conditions in real blood vessels, the entire operation process from embolic agent delivery and navigation to targeted coagulation embolization is fully reproduced. This allows for intuitive and comprehensive verification of the active navigation capability, magnetically controlled movement performance, autoradiography effect, and reliability of targeted coagulation embolization of the embolic agent, accurately reflecting the actual performance of the embolic agent in different application scenarios.

[0088] The above description is merely a preferred embodiment of this disclosure and an explanation of the technical principles employed. Those skilled in the art should understand that the scope of this disclosure is not limited to technical solutions formed by specific combinations of the above-described technical features, but should also cover other technical solutions formed by arbitrary combinations of the above-described technical features or their equivalents without departing from the above-described concept. For example, technical solutions formed by substituting the above features with (but not limited to) technical features disclosed in this disclosure that have similar functions.

Claims

1. A magnetically responsive embolic agent, comprising: The first alloy and the second alloy are prepared by mixed alloying, wherein the first alloy is a eutectic alloy composed of metallic indium and metallic tin, and the second alloy is a eutectic alloy composed of metallic gallium, metallic indium and metallic tin. Ferromagnetic particles are uniformly dispersed within the alloyed first and second alloys.

2. The magnetically responsive embolic agent according to claim 1, wherein, The melting points of the first alloy and the second alloy are greater than or equal to 42 degrees Celsius and less than or equal to 45 degrees Celsius.

3. The magnetically responsive embolic agent according to claim 2, wherein, The first and second alloys are alloyed with a supercooling of 10 degrees Celsius to exhibit a fluid, cold metastable state in an environment within 10 degrees Celsius below the melting point.

4. The magnetically responsive embolic agent according to claim 3, wherein, The size of the ferromagnetic particles is at the micrometer level; The ferromagnetic particles are used to respond to a preset magnetic field outside the embolic agent and disrupt the cold metastable state, so as to solidify the first alloy and the second alloy, which are alloyed below the melting point and have fluidity.

5. The magnetically responsive embolic agent according to claim 1, wherein, The ferromagnetic particles are used to control the movement of the first and second alloys, which are alloyed, based on a preset magnetic field outside the embolic agent.

6. A method for preparing an embolic agent, comprising: The first alloy and the second alloy are mixed in a preset mass ratio and alloyed at a preset temperature to obtain a mixed alloy matrix. The first alloy is a eutectic alloy composed of metallic indium and metallic tin, and the second alloy is a eutectic alloy composed of metallic gallium, metallic indium and metallic tin. The mixed alloy matrix and ferromagnetic particles are placed in a hydrochloric acid solution and stirred at 60 degrees Celsius to uniformly disperse the ferromagnetic particles in the mixed alloy matrix and remove the oxide layer on the surface of the mixed alloy matrix, thereby obtaining a magnetically responsive embolic agent.

7. A test method for an embolic agent, comprising: The embolic agent is melted into a liquid state at an temperature greater than 45 degrees Celsius. The liquid embolic agent is introduced into a pre-set vascular model, which provides an ambient temperature of 37 degrees Celsius, and the embolic agent exhibits a fluid, cold metastable state within the vascular model. The movement of the cold metastable embolic agent within the vascular model is controlled by a preset magnetic field; In response to the cold metastable state of the embolic agent, it moves to the target location within the vascular model, and the high-frequency perturbation of the magnetic field disrupts the cold metastable state of the embolic agent to accelerate its coagulation.

8. The method according to claim 7, wherein, The vascular model includes multiple simulated blood vessels of different diameters, with the connections between these vessels forming different turning angles; and The method of controlling the movement of the cold metastable embolic agent within the vascular model using a preset magnetic field includes: The embolic agent is controlled to move in simulated blood vessels of different diameters and at joints with different turning angles using a preset magnetic field.

9. The method according to claim 8, wherein, At least one of the simulated blood vessels contains dynamic water flows with different velocities; as well as The method of controlling the movement of the cold metastable embolic agent within the vascular model using a preset magnetic field includes: The embolic agent is controlled to move downstream and upstream at different flow rates using a preset magnetic field.

10. The method according to claim 7, wherein, After the embolic agent in a cold metastable state is controlled to move within the vascular model using a preset magnetic field, the method further includes: The mobility of the embolic agent was detected using X-rays; After disrupting the cold metastable state of the embolic agent by utilizing the high-frequency perturbation of the magnetic field, the method further includes: The ability of the embolic agent to block the target location after solidification is detected using X-rays.

Images